ImmunoGen said that it started clinical testing with its EGFR-targeting ADC, IMGN289, a novel Antibody-drug Conjugate (ADC). The trial drug represents a potential new treatment for lung, head and neck, and other EGFR-positive solid tumors, including ones not effectively treated with EGFR-directed therapies today.

IMGN289 will be evaluated in a multi-center, Phase I trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anticancer activity of the compound, administered weekly, in patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck cancer (SCCHN), or other EGFR-positive solid tumors.

Once its maximum tolerated dose is defined in the dose-finding part of the trial, the activity of IMGN289 will be evaluated in disease-specific patient cohorts. The ones planned currently include SCCHN, squamous cell NSCLC, and NSCLC resistant to EGFR inhibitors.

Advertisement #4